Drugs / TZP-102
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01664637 | Aug 2012 → Jan 2013 | gastroparesis | Tranzyme, Inc. | Terminated | Missed primary |
| Phase 2 | NCT01452815 | Sep 2011 → Nov 2012 | gastroparesis, type 1 diabetes mellitus, type 2 diabetes mellitus | Tranzyme, Inc. | Completed | Missed primary |
| Phase 2 | NCT00889486 | Apr 2009 → Apr 2010 | diabetes mellitus, gastroparesis | Tranzyme, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TZP-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00889486 ↗ |
| Action | Activate | “TZP-102, a potent, oral, ghrelin receptor agonist” PMID 23848826 ↗ Jul 20131“Ghrelin receptor agonist” CHEMBL4594424 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL4594424 ↗ |
| Route | Oral | “taken orally once per day” NCT00889486 ↗ |
| Target | GHSR | “Ghrelin receptor agonist” CHEMBL4594424 ↗ |